Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer 2007 Aug 15;121(4):767-75
Date
04/07/2007Pubmed ID
17415708DOI
10.1002/ijc.22701Scopus ID
2-s2.0-34547093157 (requires institutional sign-in at Scopus site) 59 CitationsAbstract
In search of tumor suppressor genes in papillary thyroid carcinoma (PTC), we previously used gene expression profiling to identify genes underexpressed in tumor compared with paired unaffected tissue. While searching for loss of heterozygosity (LOH) in genomic regions harboring candidate tumor suppressor genes, we detected LOH in a approximately 20 kb region around marker D9S176. Several ESTs flanking D9S176 were underexpressed in PTC tumors, and for one of the ESTs, downregulation was highly associated with the activating BRAF mutation V600E, the most common genetic lesion in PTC. A novel gene, NAMA, (noncoding RNA associated with MAP kinase pathway and growth arrest) containing the affected EST was cloned and characterized. NAMA is weakly expressed in several human tissues, and the spliced forms are primarily detected in testis. Several characteristics of NAMA suggest that it is a nonprotein coding but functional RNA; it has no long open reading frames (ORFs); the exons exhibit low sequence identity in the evolutionarily conserved regions; it is inducible by knockdown of BRAF, inhibition of the MAP kinase pathway, growth arrest and DNA damage in cancer cell lines. We suggest that NAMA is a noncoding RNA associated with growth arrest.
Author List
Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, Pellegata N, Chapelle Ade LMESH terms used to index this publication - Major topics in bold
ApoptosisCarcinoma, Papillary
Cell Line, Tumor
Cell Proliferation
Down-Regulation
Humans
Loss of Heterozygosity
MAP Kinase Signaling System
Male
Mutation
Proto-Oncogene Proteins B-raf
RNA
RNA, Untranslated
Reverse Transcriptase Polymerase Chain Reaction
Thyroid Neoplasms
